Advancing antihypertensive drug development

作者：Fay Pu, Yanrong Liu, Fozia Ahmed, Xin Wang, Darren Green, Hongyuan Zhang · 发表于：British Journal of Pharmacology · 年份：2025 · DOI：10.1111/bph.70063 · 被引用次数：10 · 研究领域：Hormonal Regulation and Hypertension、Blood Pressure and Hypertension Studies、Renin-Angiotensin System Studies

Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment resistance, adverse effects, and adherence challenges. This review highlights innovative approaches in hypertension management. Aldosterone synthase inhibitors (ASIs) and non‐steroidal mineralocorticoid receptor antagonists improve blood pressure control and offer cardiorenal benefits while reducing adverse effects including hyperkalaemia. Endothelin receptor antagonists show promise in resistant hypertension by addressing vasoconstrictive pathways. RNA‐based therapies, like zilebesiran, provide a novel approach to suppress angiotensinogen, offering durable antihypertensive effects with less frequent dosing. Additional advances include AT 2 receptor agonists, ACE2/Angiotensin‐(1–7)/MAS receptor activators and NAD + boosting compounds, which target key mechanisms of vascular dysfunction and ageing‐related hypertension. Gut microbiome‐targeted therapies and fixed‐dose combination pills are also discussed for their potential to enhance blood pressure control and patient adherence. These emerging therapies not only aim to lower blood pressure but also address underlying pathophysiological mechanisms, offering a precision‐focussed approach to treatment. By critically analysing these developments, this review provides insights into how n...